What Yatsen Doubters Saw Before A 68% Fall

Yatsen’s latest headline came from Perth, where it set a record with 20 research presentations at the 36th IFSCC Congress, showcasing work across ingredients, skin microbiome, and new testing methods. Holding Yatsen over the past year would have meant a 68.3% loss, including dividends. If you had committed fresh capital on 30 October 2025, how should this mix of scientific ambition and weaker recent profitability shape expectations now?

Yatsen has already moved. See which of 30 high quality undervalued stocks still trade below our estimates.

The Two Yatsen Stories Investors Were Debating

The shares cost US$7.15 at the start of the period. Anyone looking at Yatsen then faced two very different stories about what might come next.

One view argued that Asian skincare demand and better digital reach could support a Fair Value of US$9.18. This was a notional price based on assumptions such as revenue growth of 15.5% a year and profit margins eventually reaching 10.8%.

A contrasting view pointed to macro and regulatory pressure, with a Fair Value of US$3.4. This was rooted in concerns that higher compliance costs could weigh on profitability even if revenue grew 18.4% a year.

What The Results Changed For The Yatsen Debate

The headline from the period was scientific. Yatsen took 20 research slots at the IFSCC Congress, which supported the earlier focus on heavy R&D and product development. The financial update pulled the other way. Revenue reached CNY 1,142.18m in Q2 2026 versus CNY 1,086.732m a year earlier, yet the business still reported a larger net loss and a weaker net margin that moved from a 1.6% loss to an 8.0% loss. Overall, the evidence pointed in both directions.

The key takeaway is portable to other cases. When a thesis relies on future profitability, it can be useful to track net income and net margin alongside any developments in science or brand positioning. For another growth story, one approach is to compare earlier expectations for margin recovery with what later filings report, and to treat ongoing losses as a signal that the profitability part of the case remains unproven.

What You Would Be Paying For In Yatsen Today

Today Yatsen trades at US$2.25, and this Narrative’s Fair Value sits above that quote based on its own set of assumptions rather than hard fact.

The Narrative leans on skincare mix, science-led branding, and potential marketing efficiency. A buyer now would need to believe that R&D, channel shifts, and cost control can turn the recent fall into a chance rather than a warning.

"The current valuation implies that Yatsen Holding is priced as if its skincare led growth, reinforced R&D credentials, and liquidity position will not translate into a durable improvement in earnings power for shareholders."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

One Step Beyond Yatsen

Yatsen puts science upfront, from ingredients to testing methods and claims. You could also look at who builds a broader everyday platform around similar themes.

Across personal care, another group is leaning into premium, science backed products. It focuses on beauty, wellbeing and hygiene that show up in daily routines.

Your skincare thesis on Yatsen might rhyme with that wider need. Consumers still want cleaner clothes, protected skin, practical wellness and trusted clinical stories.

That other business is also putting money into research and digital factories. The open question is how far this mix of scale, science and branding can shift what routine products are worth.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 23% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com